What's new in the treatment of serious MRSA infection?
Natasha E Holmes, Benjamin P Howden
CURRENT OPINION IN INFECTIOUS DISEASES | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
PURPOSE OF REVIEW: Vancomycin has been the cornerstone of treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections. This review describes new MRSA-active antibiotics that have recently been introduced and highlights emerging resistance. RECENT FINDINGS: Elevations in the vancomycin minimum inhibitory concentration within the susceptible range are associated with treatment failure and mortality in the treatment of MRSA infections. Ceftaroline and ceftobiprole are anti-MRSA cephalosporins and are noninferior to comparator agents in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and pneumonia. Tedizolid is more potent than linezolid, has improve..View full abstract
Awarded by National Health and Medical Research Council
Awarded by National Health and Medical Research Council Career Development Fellowship
N.E.H. is supported by a National Health and Medical Research Council Early Career Fellowship (APP1073378). B.P.H. is supported by a National Health and Medical Research Council Career Development Fellowship (APP1023526).